Merck & Co., Inc. $MRK Stock: Signal Advisors Wealth LLC Boosts Stake

Signal Advisors Wealth LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 32.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,224 shares of the company’s stock after buying an additional 5,445 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Merck & Co., Inc. were worth $3,229,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. GEM Asset Management LLC acquired a new position in Merck & Co., Inc. in the third quarter valued at about $224,000. Foster Group Inc. grew its stake in Merck & Co., Inc. by 8.8% during the third quarter. Foster Group Inc. now owns 5,938 shares of the company’s stock worth $863,000 after buying an additional 480 shares during the last quarter. B. Riley Wealth Advisors Inc. grew its stake in Merck & Co., Inc. by 20.6% during the third quarter. B. Riley Wealth Advisors Inc. now owns 35,238 shares of the company’s stock worth $5,120,000 after buying an additional 6,012 shares during the last quarter. Krilogy Financial LLC increased its holdings in shares of Merck & Co., Inc. by 7.4% during the third quarter. Krilogy Financial LLC now owns 43,376 shares of the company’s stock worth $6,309,000 after buying an additional 2,998 shares in the last quarter. Finally, RHS Financial LLC acquired a new stake in shares of Merck & Co., Inc. during the third quarter worth approximately $266,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck will present first-time results from three pivotal Phase 3 oncology trials at the ESMO 2026 congress, alongside more than 90 additional abstracts covering over 20 tumor types. The disclosures could provide investors with evidence of pipeline progress and support long-term growth beyond the company’s existing portfolio. Merck ESMO 2026 announcement
• Positive Sentiment: Citigroup raised its price target for MRK to $145 from $125, although it maintained a neutral rating. The higher target reflects some improvement in the firm’s valuation view, even as the limited implied upside signals caution.
• Neutral Sentiment: Merck appointed Paul J. Diaz to its board of directors. The appointment adds healthcare-management experience but is unlikely to materially change near-term earnings expectations. Paul J. Diaz elected to Merck board
• Neutral Sentiment: Merck is scheduled to report third-quarter results in about two weeks. Analysts expect single-digit EPS growth, making the report and management’s guidance important catalysts for the stock. Merck upcoming earnings expectations
• Negative Sentiment: Jefferies cut its peak-sales forecast for remigromig by 60% after trial details showed smaller numerical vision improvements than an established competitor and raised safety concerns. Although the drug met the statistical non-inferiority threshold, the reduced commercial opportunity weighs on Merck’s growth outlook. Jefferies remigromig sales forecast cut
• Negative Sentiment: Erste Group modestly lowered its FY2026 and FY2027 EPS estimates, reinforcing caution around Merck’s earnings trajectory. The stock’s decline during the session appears consistent with investors focusing on these forecast reductions and remigromig concerns despite the positive oncology pipeline news.

Insider Buying and Selling

In other news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This represents a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $141.97 on Wednesday. The business has a fifty day moving average of $144.52 and a 200-day moving average of $128.73. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92. The firm has a market cap of $350.27 billion, a PE ratio of 113.58, a price-to-earnings-growth ratio of 6.72 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.4%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada cut their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research note on Monday. Rothschild & Co Redburn boosted their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Weiss Ratings upgraded Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Barclays increased their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Wolfe Research raised their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $151.92.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.